ClinicalTrials.gg

Program

CMAB007

A development code. Also written as “Process-Changed CMAB007”.

Its studies are mostly in Chronic Urticaria · Asthma, led by 2 companies.

Furthest: phase 3, since Apr 7, 20244 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Taizhou Mabtech Pharmaceutical30 open or runningphase 3since Apr 7, 2024May 31, 2023none ahead
Shanghai Biomabs Pharmaceutical10 open or runningphase 3since Mar 7, 2018Mar 7, 2018none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 7, 2018First study: phase 3 study in AsthmaNew to Shanghai Biomabs PharmaceuticalShanghai Biomabs Pharmaceutical · NCT03468790 · 393 enrolled · China
  2. May 31, 2023Taizhou Mabtech Pharmaceutical's first study: phase 1 study in Healthy VolunteersNew to Taizhou Mabtech PharmaceuticalTaizhou Mabtech Pharmaceutical · NCT05897008 · 114 enrolled · China
  3. Apr 7, 2024Phase 3 study in Chronic UrticariaTaizhou Mabtech Pharmaceutical · NCT06365879 · 392 enrolled · China
  4. Nov 17, 2025Phase 1 study in Healthy Volunteers (HV)Taizhou Mabtech Pharmaceutical · NCT07246252 · 114 enrolled · China

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07246252Healthy Volunteers (HV) · China1CompletedTaizhou Mabtech PharmaceuticalSep 30, 2024114
NCT06365879Chronic Urticaria · China3CompletedTaizhou Mabtech PharmaceuticalJan 29, 2026392
NCT05897008Healthy Volunteers · China1CompletedTaizhou Mabtech PharmaceuticalJun 27, 2022114
NCT03468790Asthma · China3CompletedShanghai Biomabs PharmaceuticalJan 12, 2021393

How it is read

Names in the registry

  • “CMAB007”, 3 entries
  • “Process-Changed CMAB007”, 1 entry

Codes read as this program: CMAB007.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.